about
Canine Leishmaniasis Progression is Associated with Vitamin D Deficiency.The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.Higher expression of CCL2, CCL4, CCL5, CCL21, and CXCL8 chemokines in the skin associated with parasite density in canine visceral leishmaniasis.Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs.A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons.The immunopathology of canine vector-borne diseases.Assessment of the Effects of a Novel Herbal Immunomodulator Drug (IMOD) on Cytokine Profiles in Experimental Canine Visceral Leishmaniasis: a Preliminary SurveyOne-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasisCanine Antibodies against Salivary Recombinant Proteins of Phlebotomus perniciosus: A Longitudinal Study in an Endemic Focus of Canine Leishmaniasis.Leishmania infantum-specific production of IFN-γ and IL-10 in stimulated blood from dogs with clinical leishmaniosis.Insights on adaptive and innate immunity in canine leishmaniosis.Cytokine and Phenotypic Cell Profiles of Leishmania infantum Infection in the Dog.The inflammatory cytokine effect of Pam3CSK4 TLR2 agonist alone or in combination with Leishmania infantum antigen on ex-vivo whole blood from sick and resistant dogs.Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB/c miceField trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates.Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.Clinical and immunopathological findings during long term follow-up in Leishmania infantum experimentally infected dogs.Scientific Opinion on canine leishmaniosisVaccines for canine leishmaniasisBiomarkers Associated With Exposure, Infection, and Disease in DogsClinically relevant advances in European canine leishmaniosis
P2860
Q33794111-2049E001-9C61-4491-A8B1-176C045A48ECQ33861384-35E0FBB3-758B-4327-8289-F52F91A560F8Q34233887-C79A1731-F183-4F63-85C7-09B6FFA3D929Q34314496-D45A046A-BB7A-47AA-AF48-BDE55722DAD8Q34315159-C5D4DC75-B91D-40CB-987D-106DBFFDD2DAQ34961388-7A2C9C1D-D42E-4BBD-A2A2-3BAE9B583AACQ35047301-8E4ECC6D-705E-47AE-B7DE-15360FE122E7Q35518943-60781FE0-2D7E-45A7-9696-E6D441218468Q35674577-A3947A3C-6B68-4AAF-9ED4-E218395B7AE7Q36969157-885B7F6C-E966-4D8B-9F89-B3EE2AEBD40AQ37605215-E5A041DB-4DCC-48F3-B9A3-4D559B2217DAQ39205564-C183005C-F078-4050-A901-B1752E5D0FA4Q40296327-A32EE9AB-13C0-4BF1-A444-991A1FA9FE1DQ40572422-4525DD6C-3C41-4106-9B6A-3AFCA46AF2E9Q41993713-2448B29F-03D7-49AD-8291-9F4FD9086867Q42653980-ED7CA8ED-78DA-4A5D-A428-376EE49AE8F3Q47096541-FB99B31B-0B8C-4AB8-9833-BFE43B3F207AQ47156873-968975A7-8A32-4F19-BDCD-1D0FEF15C213Q56769198-62623FF4-6DDD-43E0-A716-43561A80FA3FQ57160072-CE71842B-DA08-4108-BA15-545261F3883FQ57587670-E39DBAB7-8A6F-4DD9-BE6C-62774AA35521
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytokine profiles in canine visceral leishmaniasis.
@en
Cytokine profiles in canine visceral leishmaniasis.
@nl
type
label
Cytokine profiles in canine visceral leishmaniasis.
@en
Cytokine profiles in canine visceral leishmaniasis.
@nl
prefLabel
Cytokine profiles in canine visceral leishmaniasis.
@en
Cytokine profiles in canine visceral leishmaniasis.
@nl
P1476
Cytokine profiles in canine visceral leishmaniasis.
@en
P356
10.1016/J.VETIMM.2008.10.310
P577
2008-10-17T00:00:00Z